References
- Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O,
Bray F. International variation in prostate cancer incidence and
mortality rates. Eur Urol. 2012;61(6):1079–92.
- Cipolla-Neto J, Amaral FGD. Melatonin as a Hormone: New Physiological
and Clinical Insights. Endocr Rev. 2018 Dec 1;39(6):990-1028. doi:
10.1210/er.2018-00084. PMID: 30215696.
- M.Singh, H.R. Jadhav. Melatonin: functions and ligands. Drug Discov.
Today. 2014;19(9):1410-1418.
- Claustrat B, Leston J. Melatonin: Physiological effects in humans.
Neurochirurgie. 2015 Apr-Jun;61(2-3):77-84. doi:
10.1016/j.neuchi.2015.03.002. Epub 2015 Apr 20. PMID: 25908646.
- de Weerth C, Zijl RH, Buitelaar JK. Development of cortisol circadian
rhythm in infancy. Early Hum Dev. 2003 Aug;73(1-2):39-52. doi:
10.1016/s0378-3782(03)00074-4. PMID: 12932892.
- Law R, Hucklebridge F, Thorn L, Evans P, Clow A. State variation in
the cortisol awakening response. Stress. 2013 Sep;16(5):483-92. doi:
10.3109/10253890.2013.817552. Epub 2013 Jul 29. PMID: 23805796.
- Pierre K, Rao RT, Hartmanshenn C, Androulakis IP. Modeling the
Influence of Seasonal Differences in the HPA Axis on Synchronization
of the Circadian Clock and Cell Cycle. Endocrinology. 2018 Apr
1;159(4):1808-1826. doi: 10.1210/en.2017-03226. PMID: 29444258; PMCID:
PMC6044315.
- Gómez-Acebo I, Dierssen-Sotos T, Papantoniou K, García-Unzueta MT,
Santos-Benito MF, Llorca J. Association between exposure to rotating
night shift versus day shift using levels of 6-sulfatoxymelatonin and
cortisol and other sex hormones in women. Chronobiol Int. 2015
Feb;32(1):128-35. doi: 10.3109/07420528.2014.958494. Epub 2014 Sep 12.
PMID: 25216206.
- DeSantis AS, DiezRoux AV, Hajat A, Aiello AE, Golden SH, Jenny NS,
Seeman TE, Shea S. Associations of salivary cortisol levels with
inflammatory markers: the Multi-Ethnic Study of Atherosclerosis.
Psychoneuroendocrinology. 2012 Jul;37(7):1009-18. doi:
10.1016/j.psyneuen.2011.11.009. Epub 2011 Dec 16. PMID: 22178583;
PMCID: PMC3358540.
- Li Y, Li S, Zhou Y, Meng X, Zhang JJ, Xu DP, Li HB. Melatonin for the
prevention and treatment of cancer. Oncotarget. 2017 Jun
13;8(24):39896-39921. doi: 10.18632/oncotarget.16379. PMID: 28415828;
PMCID: PMC5503661.
- Talib WH. Melatonin and Cancer Hallmarks. Molecules. 2018 Feb
26;23(3):518. doi: 10.3390/molecules23030518. PMID: 29495398; PMCID:
PMC6017729.
- Kubatka P, Zubor P, Busselberg D, Kwon TK, Adamek M, Petrovic D,
Opatrilova R, Gazdikova K, Caprnda M, Rodrigo L, Danko J, Kruzliak P.
Melatonin and breast cancer: Evidences from preclinical and human
studies. Crit Rev Oncol Hematol. 2018 Feb;122:133-143. doi:
10.1016/j.critrevonc.2017.12.018. Epub 2017 Dec 29. PMID: 29458781.
- Veiga ECA, Simões R, Valenti VE, Cipolla-Neto J, Abreu LC, Barros EPM,
Sorpreso ICE, Baracat MCP, Baracat EC, Soares Junior JM. Repercussions
of melatonin on the risk of breast cancer: a systematic review and
meta-analysis. Rev Assoc Med Bras (1992). 2019 Jun 3;65(5):699-705.
doi: 10.1590/1806-9282.65.5.699. PMID: 31166448.
- Mayo JC, Hevia D, Quiros-Gonzalez I, Rodriguez-Garcia A,
Gonzalez-Menendez P, Cepas V, Gonzalez-Pola I, Sainz RM. IGFBP3 and
MAPK/ERK signaling mediates melatonin-induced antitumor activity in
prostate cancer. J Pineal Res. 2017 Jan;62(1). doi: 10.1111/jpi.12373.
Epub 2016 Nov 9. PMID: 27736013.
- Calastretti A, Gatti G, Lucini V, Dugnani S, Canti G, Scaglione F,
Bevilacqua A. Melatonin Analogue Antiproliferative and Cytotoxic
Effects on Human Prostate Cancer Cells. Int J Mol Sci. 2018 May
18;19(5):1505. doi: 10.3390/ijms19051505. PMID: 29783631; PMCID:
PMC5983593.
- Calastretti A, Gatti G, Lucini V, Dugnani S, Canti G, Scaglione F,
Bevilacqua A. Melatonin Analogue Antiproliferative and Cytotoxic
Effects on Human Prostate Cancer Cells. Int J Mol Sci. 2018 May
18;19(5):1505. doi: 10.3390/ijms19051505. PMID: 29783631; PMCID:
PMC5983593.
- Calastretti A, Gatti G, Lucini V, Dugnani S, Canti G, Scaglione F,
Bevilacqua A. Melatonin Analogue Antiproliferative and Cytotoxic
Effects on Human Prostate Cancer Cells. Int J Mol Sci. 2018 May
18;19(5):1505. doi: 10.3390/ijms19051505. PMID: 29783631; PMCID:
PMC5983593.
- Rao AR, Motiwala HG, Karim OM. The discovery of prostate-specific
antigen. BJU Int. 2008 Jan;101(1):5-10. doi:
10.1111/j.1464-410X.2007.07138.x. Epub 2007 Aug 30. PMID: 17760888.
- Rzepka-Migut B, Paprocka J. Melatonin-Measurement Methods and the
Factors Modifying the Results. A Systematic Review of the Literature.
Int J Environ Res Public Health. 2020 Mar 15;17(6):1916. doi:
10.3390/ijerph17061916. PMID: 32183489; PMCID: PMC7142625.
- Xiao WJ, Zhu Y, Zhu Y, Dai B, Ye DW. Evaluation of clinical staging of
the American Joint Committee on Cancer (eighth edition) for prostate
cancer. World J Urol. 2018 May;36(5):769-774. doi:
10.1007/s00345-018-2183-0. Epub 2018 Jan 25. PMID: 29372356.
- Bartsch C, Bartsch H, Schmidt A, Ilg S, Bichler KH, Flüchter SH.
Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and
urine of primary prostate cancer patients: evidence for reduced pineal
activity and relevance of urinary determinations. Clin Chim Acta. 1992
Aug 31;209(3):153-67. doi: 10.1016/0009-8981(92)90164-l. PMID:
1395046.
- Sigurdardottir LG, Markt SC, Rider JR, Haneuse S, Fall K, Schernhammer
ES, Tamimi RM, Flynn-Evans E, Batista JL, Launer L, Harris T, Aspelund
T, Stampfer MJ, Gudnason V, Czeisler CA, Lockley SW, Valdimarsdottir
UA, Mucci LA. Urinary melatonin levels, sleep disruption, and risk of
prostate cancer in elderly men. Eur Urol. 2015 Feb;67(2):191-4. doi:
10.1016/j.eururo.2014.07.008. Epub 2014 Aug 5. PMID: 25107635; PMCID:
PMC4318783.
- Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer
agent: cellular, biochemical, and molecular mechanisms of action and
their implications for circadian-based cancer therapy. Curr Top Med
Chem. 2002 Feb;2(2):113-32. doi: 10.2174/1568026023394407. PMID:
11899096.
- Reiter RJ, Tan DX, Erren TC, Fuentes-Broto L, Paredes SD.
Light-mediated perturbations of circadian timing and cancer risk: a
mechanistic analysis. Integr Cancer Ther. 2009 Dec;8(4):354-60. doi:
10.1177/1534735409352026. PMID: 20042411.
- Pariollaud M, Lamia KA. Cancer in the Fourth Dimension: What Is the
Impact of Circadian Disruption? Cancer Discov. 2020
Oct;10(10):1455-1464. doi: 10.1158/2159-8290.CD-20-0413. Epub 2020 Sep
15. PMID: 32934020; PMCID: PMC7541588.
- Blask DE, Brainard GC, Dauchy RT, Hanifin JP, Davidson LK, Krause JA,
Sauer LA, Rivera-Bermudez MA, Dubocovich ML, Jasser SA, Lynch DT,
Rollag MD, Zalatan F. Melatonin-depleted blood from premenopausal
women exposed to light at night stimulates growth of human breast
cancer xenografts in nude rats. Cancer Res. 2005 Dec
1;65(23):11174-84. doi: 10.1158/0008-5472.CAN-05-1945. PMID: 16322268.
- Blask DE, Dauchy RT, Brainard GC, Hanifin JP. Circadian
stage-dependent inhibition of human breast cancer metabolism and
growth by the nocturnal melatonin signal: consequences of its
disruption by light at night in rats and women. Integr Cancer Ther.
2009 Dec;8(4):347-53. doi: 10.1177/1534735409352320. PMID: 20042410.
- Jung-Hynes B, Huang W, Reiter RJ, Ahmad N. Melatonin resynchronizes
dysregulated circadian rhythm circuitry in human prostate cancer
cells. J Pineal Res. 2010 Aug;49(1):60-8. doi:
10.1111/j.1600-079X.2010.00767.x. Epub 2010 May 27. PMID: 20524973;
PMCID: PMC3158680.
- Jung-Hynes B, Schmit TL, Reagan-Shaw SR, Siddiqui IA, Mukhtar H, Ahmad
N. Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative
effects against prostate cancer in vitro in culture and in vivo in
TRAMP model. J Pineal Res. 2011 Mar;50(2):140-9. doi:
10.1111/j.1600-079X.2010.00823.x. Epub 2010 Nov 9. PMID: 21062352;
PMCID: PMC3052633.
- Cole TJ, Short KL, Hooper SB. The science of steroids. Semin Fetal
Neonatal Med. 2019 Jun;24(3):170-175. doi: 10.1016/j.siny.2019.05.005.
Epub 2019 May 23. PMID: 31147162.
- Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB.
Inflammation and cancer. Ann Afr Med. 2019 Jul-Sep;18(3):121-126. doi:
10.4103/aam.aam_56_18. PMID: 31417011; PMCID: PMC6704802.
- Mirick DK, Bhatti P, Chen C, Nordt F, Stanczyk FZ, Davis S. Night
shift work and levels of 6-sulfatoxymelatonin and cortisol in men.
Cancer Epidemiol Biomarkers Prev. 2013 Jun;22(6):1079-87. doi:
10.1158/1055-9965.EPI-12-1377. Epub 2013 Apr 5. PMID: 23563887; PMCID:
PMC4772962.
- Wetterbuerg L, Beck-Friis J, Aperia B, Petterson U. Melatonin/cortisol
ratio in depression. Lancet. 1979 Dec 22-29;2(8156-8157):1361. doi:
10.1016/s0140-6736(79)92837-x. PMID: 92692.
- Vezyraki P, Vlachaki A, Baltogiannis D, Batistatou A, Tsampalas S, V
Simos Y, Kaltsas A, Pappas P, Dounousi E, Ragos V, Tsiambas E, Peschos
D. Impact of total PSA and percent free PSA in the differentiation of
prostate disease: a retrospective comparative study implicating
neoplastic and non-neoplastic entities. J BUON. 2019
Sep-Oct;24(5):2107-2113. PMID: 31786882.
- Fu S, Zhang X, Niu Y, Wang RT. Prostate Specific Antigen, Mean
Platelet Volume, and Platelet Distribution Width in Combination to
Discriminate Prostate Cancer from Benign Prostate Hyperplasia. Asian
Pac J Cancer Prev. 2018 Mar 27;19(3):699-702. doi:
10.22034/APJCP.2018.19.3.699. PMID: 29580043; PMCID: PMC5980844.
- Costa P, Ben Naoum K, Boukaram M, Wagner L, Louis JF. Hyperplasie
bénigne de la prostate (HBP) : prévalence en médecine générale et
attitude pratique des médecins généralistes français. Résultats d’une
etude réalisée auprès de 17.953 patients [Benign prostatic
hyperplasia (BPH): prevalence in general practice and practical
approach of French general practitioners. Results of a study based on
17,953 patients]. Prog Urol. 2004 Feb;14(1):33-9. French. PMID:
15098749.
Table 1. Demographic characteristics of all participants.